conclusions: An evidence-based approach to the preoperative characterization of any adnexal mass should incorporate the use of IOTA Simple Rules or the LR2 model, particularly for women of reproductive age.
Introduction
Detecting ovarian cancer in primary care is challenging because of the nonspecific nature of the symptoms. Once women have reached secondary care, characterizing ovarian pathology is fundamental to optimizing patient management (Vergote et al., 2001; Bristow and Berek, 2006; Woo et al., 2012) . Ovarian tumours are a common clinical entity that affects women of all ages (Alcazar et al., 2005) . It has been estimated that in the USA a woman has a 5-10% lifetime risk of undergoing surgery for this condition (Curtin, 1994) . Although, a priori, most tumours are benign, it is of paramount importance to correctly characterize whether ovarian masses constitute benign or malignant disease. This is particularly the case in premenopausal women where preservation of fertility is an important issue. Although these women are rarely thought to have cancer, they in fact account for up to 20% of all ovarian malignancies (Bristow et al., 2004; Siegel et al., 2011) .
Patients with diagnosed ovarian cancer should be treated in specialist centres that provide the most comprehensive cancer care (Woo et al., 2012) , whereas for benign ovarian masses expectant or conservative surgical management may be warranted due to reduced morbidity and the importance of fertility preservation (Carley et al., 2002; Tinelli et al., 2006) . Even in selected cases of early stage invasive disease or borderline ovarian tumours (BOT), conservative treatment is a therapeutic option in young women who want to preserve their childbearing capacity (Morice et al., 2003; Tinelli et al., 2006; Daraï et al., 2013) . Moreover, since 'oncofertility' was introduced in 2006 as a well-identified subspecialty that focuses on cancer survivors, ovarian cancer characterization has become more important for exploring all fertility preservation options before any cancer surgery (Woodruff, 2007) .
Unnecessary surgery or overly radical surgical interventions with abrupt loss of childbearing potential in young women are all significant risks to patients with a cyst that is inappropriately characterized, whilst the consequences of failing to recognize a cyst as malignant significantly impact on prognosis (Vergote et al., 2001; Fanfani et al., 2004; Yazbek et al., 2008) .
Prediction models have been developed to assist clinicians to triage patients to appropriate treatment pathways; however, none has gained universal acceptance in routine daily practice. For example in the UK, the National Institute of Clinical Excellence and Royal College of Obstetrics and Gynaecology guidelines suggest using the Risk of Malignancy Index (RMI) as a primary diagnostic tool in secondary care, whereas the American Congress of Obstetrics and Gynaecology recommends using a combination of clinical, demographic, laboratory and imaging variables (Dearking et al., 2007; RCOG guideline, green top 34, 2010; NICE clinical guidelines CG122, 2011) . The current test performance of these algorithms depends heavily upon biomarkers (serum CA 125 levels), and this limits their utility, particularly in women of reproductive age . Serum CA 125 levels are frequently normal in borderline tumours and early stage invasive ovarian cancer (Engelen et al., 2000; Gotlieb et al., 2000) , and can show a falsepositive increase in numerous benign tumours or conditions that irritate the pelvic peritoneum (e.g. endometriosis, fibroids, pregnancy, infection and surgery) (Sevinc et al., 2007) . More recently, other biomarkers (Moore et al., 2007) have been combined into multimarker decision algorithms such as the Risk of Ovarian Malignancy Algorithm (ROMA) and OVA-1 to triage patients in both primary and secondary care (Bast et al., 2012) . Other diagnostic models have been only based on clinical information and ultrasound features. The International Ovarian Tumour Analysis (IOTA) models and rules (LR2 and Simple Rules) characterize adnexal tumours based upon the presence or absence of typical ultrasound features of malignancy (e.g. ascites, increased vascularization, solid components, tumour size, papillary projections and irregular cyst walls) (Timmerman et al., 2005 (Timmerman et al., , 2008 .
Recent systematic reviews that evaluate the diagnostic test performance of several prediction models have only reviewed the literature up to 2009 (Geomini et al., 2009; Dodge et al., 2012) . As a result numerous validation studies assessing the ROMA and the ultrasound-based models and rules (LR2 and Simple Rules) of the largest study on the classification of ovarian pathology in the literature to date (IOTA) have not been subject to detailed review. Therefore, the conclusions of these earlier reviews have important limitations and are, by definition, outdated.
The objective of this study was to conduct an up-to-date systematic review and meta-analysis that reflects the recent development of new diagnostic tests for the preoperative identification of malignant disease in women with adnexal masses.
Methods

Protocol and registration
All methods for analysis, inclusion/exclusion criteria, data extraction and quality assessment were specified in advance. The systematic review and meta-analysis was performed in accordance with recommended methods (Irwig et al., 1994; Deeks, 2001; Moher et al., 2009; Macaskill et al., 2010;  http://www.prisma-statement.org/).
Eligibility criteria
Eligible studies for qualitative data synthesis had to contain sufficient data to extract 2 × 2 contingency tables on the diagnostic test performance of prediction models that use at least two parameters (e.g. diagnostic imaging variables, biomarkers, patient demographics, etc.) to estimate the risk of malignancy in women presenting with an adnexal mass.
Studies fulfilling the following criteria were excluded: studies limited to children, adolescents or pregnant women; studies that evaluated model performance for only very specific histological subgroups of ovarian cancer (i.e. non-epithelial ovarian cancer, BOTs); studies that evaluated technical aspects of a prediction model rather than its diagnostic accuracy; studies that are reported only in abstract form and either the full text or the raw data from the study investigators were not available; studies that did not evaluate prediction models for ovarian cancer, or evaluated only models containing one parameter; studies that used duplicate data; studies that tested models in a screening setting; studies that used healthy subjects as controls; and studies in which we were unable to extract 2 × 2 tables cross-classifying the model results and histopathology. No publication status or study design restrictions were imposed.
Search and information sources
To identify eligible studies, searches were run in the following electronic databases: MEDLINE (PubMed) and EMBASE (OvidSP) from March 2008 to the date of the last search (1 October 2013). The search strategy included exactly the same search terminology for both the index test and target condition as previously described (Geomini et al., 2009 
Data collection process
Two assessors (J.K. and A.S.) independently reviewed all citations identified by the search strategy described above, first by title and abstract and if necessary by reviewing the full text of the study report, to determine eligibility. To be included in the qualitative data synthesis, the full text of each potentially relevant article was obtained and assessed to determine whether the study met the inclusion and exclusion criteria detailed above. Any disagreement was resolved by consensus. For excluded studies, reasons for exclusion were documented. The references of these excluded studies (n ¼ 50) can be found as supporting information to this review (Supplementary data, Text S1).
Data extraction and quality assessment
Both reviewers (J.K. and A.S.) independently completed a predefined data extraction sheet as discussed below whilst discrepancies were resolved by consulting a third party (B.V.C., T.B. or D.T.). Information from articles in languages other than English, Dutch, French or German was only extracted when an English abstract and required data were available. The following data were retrieved:
General information: author, journal, year of publication, cross-sectional versus case-control study design, prospective versus retrospective data collection, multicentre design and sampling method. † Total sample size of included adnexal masses, prevalence of malignancy and allocation of BOTs to benign or malignant subgroup. † Type of prediction model validated, its variables and cut-off used for test positivity. † Type of reference standard used. † Number of true positives (TPs), true negatives (TNs), false positives, false negatives. If these counts were not reported, contingency tables were reconstructed from summary estimates of sensitivity and specificity if provided. In the event that studies reported sensitivity/specificity pairs for different cut-off values, these were all registered. AUCs were also retrieved if available with their corresponding 95% confidence intervals. † Methodological quality items and types of bias were evaluated using a modified version of the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) assessment tool. This is a validated checklist for the assessment of the methodological quality of studies included in systematic reviews of diagnostic accuracy developed by the NHS Centre for Reviews and Dissemination, University of York, UK (Whiting et al., 2003) .
Statistical analysis and quantitative data synthesis
Meta-analysis was restricted to those prediction models that had been externally validated in at least two different studies on a minimum total sample of 1000 adnexal masses in order to retrieve more robust, generalizable results. Additionally, for eligible multicentre studies we contacted the corresponding authors to retrieve overall centre-specific results if these were not provided in the report. When we were not able to obtain centre-specific results, we continued with the reported pooled result. All prediction models included in the meta-analysis were developed to predict malignancy in women with any adnexal tumour, except for the ROMA algorithm, which more specifically differentiates between epithelial ovarian cancer and benign disease and so previous validation studies have systematically excluded non-epithelial malignant ovarian tumours, metastatic disease, non-ovarian primary tumours or BOTs Kim et al., 2011; Molina et al., 2011; Montagnana et al., 2011; Ruggeri et al., 2011; Kadija et al., 2012; Karlsen et al., 2012; Partheen et al., 2011; Chan et al., 2013; Sandri et al., 2013) . In order to achieve a more valid comparison between all models, we decided to only use results for those validation studies of ROMA ( Van Gorp et al., 2011; Anton et al., 2012; Presl et al., 2012; Pitta et al., 2013) that have reported diagnostic test performance for all types of adnexal malignancy. The same held true for combining dichotomized levels (elevated versus normal) of the individual biomarkers serum CA 125 and HE4, which was regarded as a 'model' according to our eligibility criteria. Although it met the predefined criteria for meta-analysis, we decided to exclude it from further analysis as only one validation study (Chang et al., 2011) reported overall test performance for this model without prior exclusion of certain histological subgroups.
In case we detected statistical inconsistencies that we were unable to clarify with the corresponding author of the original article, we excluded the study from the meta-analysis. Validation studies of prediction models that excluded BOTs or allocated BOTs to the benign cohort were not used in the quantitative data synthesis.
All individual study results were presented graphically by plotting estimates of sensitivity and specificity and their 95% confidence intervals to display the precision of the estimates and to illustrate heterogeneity between studies. For models where studies used a common cut-off point to define a positive test results, a pooled summary estimate of the expected operating point (sensitivity and specificity) and corresponding 95% confidence interval was obtained using a bivariate random effects model using the PROC GLIMMIX procedure in SAS9.2 (SAS Institute, Cary, NC, USA) (Macaskill et al., 2010) . If there was variation in the cut-off points used to define a positive test, a bivariate hierarchical summary receiver operating curve (HSROC) model was fitted using the PROC NLMIXED procedure in SAS9.2 to estimate the summary ROC curve (Macaskill et al., 2010) .
Although we intended to perform a subgroup analysis by menopausal status for all included models, this was not feasible as the majority of validation studies did not stratify their results post hoc for menopausal status. However, we had individual patient data available for pre-and postmenopausal women from two multicentre cohorts (Timmerman et al., 2010; Van Holsbeke et al., 2012; Sayasneh et al., 2013b) on which several models were evaluated, so we conducted a meta-analysis for both groups on these data to minimize the risk of introducing bias. For both cohorts, we used centre-specific data from 15 units in different clinical settings involving a total number of 1252 patients. Only units that contributed at least 3 benign and 3 malignant cases were considered in this analysis.
Results
Study selection, study characteristics and risk of bias within studies Figure 1 summarizes the process of identification and selection of studies. We retrieved a total (n ¼ 82) of 79 new research articles and three systematic reviews (Dodge et al., 2012; Li et al., 2012; Ferraro et al., 2013) in addition to the research articles contained (n ¼ 116) in the previous systematic review (Geomini et al., 2009) . These 195 validation studies have reported on 116 different prediction models for differentiating between the benign or malignant nature of an adnexal mass. Our extended search retrieved 33 new models in addition to the 83 models already derived from the previous review (Geomini et al., 2009) . Figure 2 shows a summary of the main quality characteristics of the 195 included studies according to the modified version of the QUADAS assessment tool. Overall 79% of the included studies were cross-sectional ('cohort-type'), 59% were prospective and 55% sampled consecutive women. Most studies (82%) included patients with an adnexal mass that underwent both the index test(s) and a reference standard in order to avoid verification bias. The vast majority of studies (93%) used histology as their final outcome, which in general is considered to be an acceptable reference standard. However, 63% did not report on the time interval between the index and reference test, 51% did not report withdrawal and finally 63% did not comment on blinding of the index test results.
Synthesis of results
In total 19 prediction models met our predefined criteria for further meta-analysis. Table I displays all models considered in the review with their parameters, and their total number of validation studies. Seven of them (Sassone, Lerner, Depriest, Ferrazzi, Tailor , RMI I to II) had already been extensively evaluated in the previous systematic review (Jacobs et al., 1990; Sassone et al., 1991; DePriest et al., 1993; Lerner et al., 1994; Tingulstad et al., 1996; Ferrazzi et al., 1997; Tailor et al., 1997) . In contrast, we evaluated an additional 12 models (Prö mpeler et al., 1997; Timmerman et al., 1999a Timmerman et al., , b, 2008 Tingulstad et al., 1999; Anton et al., 2012; Lou et al., 2010; Vaes et al., 2012; Van Holsbeke et al., 2012; Karlsen et al., 2012; Ong et al., 2013; Sayasneh et al., 2013b) . All models were categorized based on model type [i.e. morphological scoring system, RMI and variants (multimodal scoring system), logistic regression models, artificial neural networks, ultrasound rules and ROMA (biomarker algorithm)].
Pooled summary estimates of the expected operating point (sensitivity and specificity) at their original cut-off point and corresponding 95% confidence interval for the considered models are shown in Table II . In contrast with the other models, ROMA considers different cut-off values for pre-and post-menopausal patients. These values also change according to the assay-kits being used to measure both serum HE4 and CA125. Although, the eight available validation studies of ROMA (Moore et al., 2009 (Moore et al., , 2011 Jacob et al., 2011; Lenhard et al., 2011; Van Gorp et al., 2011; Anton et al., 2012; Presl et al., 2012; Pitta et al., 2013) used different kits, there is little variation in sensitivity and specificity (Fig. 3 ) except for one study (Pitta et al., 2013) that showed a remarkable low overall sensitivity of 56.7%. Therefore it seemed redundant to fit an HSROC curve, and we were confronted with computational problems when doing so. The multivariate index assay OVA-1 also uses different cut-off values for pre-and post-menopausal women and has been validated by two large multicentre studies (Ueland et al., 2011; Bristow et al., 2013) in the USA (Table I) . OVA-1 achieved comparable diagnostic accuracy in both studies with similar sensitivities of 92 and 93% and corresponding specificities of 54 and 43%. Forest plots of the individual study results for the other models are shown in Supplementary data, Figs S1-S5. (Fig. 5A-F) .
The performance of the models that were excluded from the quantitative data synthesis and their references (i.e. models that were only described in their original publication without further validation, models that were only validated once, or in a limited number of adnexal masses) can be found as supporting information to this review (Supplementary data, Tables SI and SII, and Text S2).
Discussion
Summary of evidence
Adding new studies from our extended search leads to different conclusions to those published previously (Geomini et al., 2009) . Following our systematic review of the literature and according to the results of the meta-analysis, we suggest that the evidence-based approach to the preoperative characterization of adnexal pathology should include the use of an ultrasound-based prediction model such as the IOTA LR2 model or ultrasound-based SR.
Strengths and limitations
The strengths of our report include the incorporation of evidence that reflects the recent development of new diagnostic tests for the preoperative identification of malignant disease in women with adnexal masses, the strict adherence to recent guidelines for diagnostic reviews (Irwig et al., 1994; Deeks, 2001; Moher et al., 2009; Macaskill et al., 2010) , and the use of advanced statistical methods to report summary estimates of sensitivity and specificity and summary ROC curves for the models under consideration (Macaskill et al., 2010) .
Like any other systematic review, this study is not without limitations. First, in an ideal setting, comparative accuracy between all considered tests or models in this review should be estimated by restricting analysis to those studies that have evaluated these tests/models in the same individuals (Macaskill et al., 2010) . However, there were too few studies that evaluated multiple tests in our meta-analysis to adopt such a general approach.
On the other hand, three recent validation studies did compare overall test performance of the IOTA LR2 model (Van Holsbeke et al., 2012; Sayasneh et al., 2013b) and IOTA SR with both RMI-1 and the ROMA algorithm (Kaijser et al., 2013c) on the same set of patients. In the first study, a total of 742 (74%) benign and 255 (26%) malignant masses were included (Van Holsbeke et al., 2012) . Showing an overall sensitivity of 92% and specificity of 86% LR2 achieved a higher diagnostic accuracy compared with the current reference test RMI-1 (sensitivity 67% and specificity 95%). The difference in AUC between LR2 and RMI-1 was 0.038 (95% CI 0.018-0.058). In Figure 2 Quality assessment of studies (n ¼ 195) Ferrazzi (Ferrazzi et al., 1997) Morphologic score (i) Wall structure, (ii) septa, (iii) vegetation, (iv) echogenicity 9 9 1814
Depriest (Depriest et al., 1993) Morphologic score (i) Tumour volume, (ii) wall structure, (iii) septal structure 5 10 1957
Lerner (Lerner et al., 1994) Morphologic score (i) Wall structure, (ii) acoustic shadows, (iii) septa, (iv) echogenicity 3 10 3035
Sassone (Sassone et al., 1991) Morphologic score Characterizing adnexal tumours before surgery the second study, which included 255 adnexal masses (malignancy rate 29%), the difference in AUC was 0.04 (95% CI 0.01 -0.07) in favour of LR2 . In this same study, a strategy of IOTA SR with classifying all inconclusive masses as malignant had an overall sensitivity of 91% and specificity of 87% compared with 72 and 94% for RMI-1, respectively . In the third study a total of 144 (40%) malignant and 216 (60%) benign adnexal masses were included (Kaijser et al., 2013c) . The overall test performance of LR2 (AUC 0.952) with a 94% sensitivity and 82% specificity was better than ROMA (AUC 0.893) with 84% sensitivity and 80% specificity. The difference in AUC was 0.059 (95% CI 0.026-0.091). The second limitation was that this meta-analysis focused on sensitivity and specificity to define the diagnostic accuracy of a test. We acknowledge that it is not always correct to base universal recommendations for For simple rules, the inconclusive cases are considered as malignant. Figure 3 Forest plot demonstrating validation studies of the ROMA algorithm. Test performance of ROMA when differentiating between all benign and malignant disease. Sens, sensitivity; LCL, lower confidence limit; UCL, upper confidence limit; Spec, specificity.
the choice of a clinical test upon these criteria. The adopted cut-offs vary between models, and we recognize that this complicates interpretation of the results as the cut-off entails an assumed relative preference for TP versus TN results (Van Calster et al., 2013) . Third, we have been unable to investigate the effect of possible sources of heterogeneity with meta-regression due to the limited number of validation studies for several prediction models. The pooled estimates of overall diagnostic test performance of our considered models should therefore be interpreted with a degree of caution. The quality assessment in our report did reveal shortcomings, especially in study design (e.g. retrospective data collection, absence of adequate verification) and quality of reporting (e.g. blinding issues, delay between index and reference test). In total 41% of all included studies were retrospective in design or did not properly report this quality item. A lack of adequate blinding (e.g. knowledge of the reference test) in these retrospective studies can bias relatively subjective index tests like transvaginal ultrasonography, and lead to overoptimistic results of diagnostic test performance (Lijmer et al., 1999) . On the other hand, the IOTA prediction models have been subject to external validation on a large sample of patients in studies with prospective and consecutive data sampling and adequate blinding procedures (Timmerman et al., 2010; Fathallah et al., 2011; Nunes et al., 2012; Van Holsbeke et al., 2012; Alcazar et al., 2013; Sayasneh et al., 2013b) .
A general criticism of the use of transvaginal ultrasonography as a diagnostic test for any woman with possible ovarian cancer is that it is subjective and its performance is dependent upon the experience and skills of the operator. The main aim of the IOTA study was to tackle this problem and produce models and rules that may help less experienced examiners replicate the results of 'experts'. There is now evidence available that suggests that ultrasound-based prediction models and rules retain their performance in the hands of both relatively inexperienced doctors and sonographers (Nunes et al., 2012; Alcazar et al., 2013; Sayasneh et al., 2013a, b) . Therefore, it should be possible for most ultrasound examiners to characterize the majority of ovarian masses with an acceptable level of test performance. In a recent multicentre validation study by operators with varied training, test performance for LR2 was better in premenopausal women than in post-menopausal women (diagnostic odds ratio of 121 and 23 in preand post-menopausal, respectively) . Similarly, when SR + SA (Simple Rules followed by subjective assessment of level II ultrasonography examiners when the rules were inconclusive) were applied, the diagnostic performance of this approach was better in premenopausal compared with post-menopausal women (diagnostic odds ratio of 100 and 82, respectively) . These findings are of importance, as this validation study suggests that the IOTA models and rules (LR2 and SR) retain their performance in premenopausal women in the hands of less experienced (level II) examiners. In contrast RMI-1 had only a diagnostic odds ratio of 30 and 37 in pre-and post-menopausal women, respectively . The discriminative performance of the IOTA models in women of reproductive age should optimize fertility preservation in these women.
In accordance with previous systematic reviews (Geomini et al., 2009; Dodge et al., 2012) , we were unable to conduct a thorough sensitivity analysis of the diagnostic accuracy of all included models in both preand post-menopausal women as the majority of validation studies have not stratified their results for menopausal status. Given the different likelihood of ovarian cancer in these groups, and its known effect on diagnostic test performance, we acknowledge that, in general, conclusions might not hold true when the data are stratified post hoc for menopausal status. However, we have been able to conduct a subgroup meta-analysis for LR2, SR and RMI-1 in pre-and post-menopausal patients using two cohorts selected by our search that evaluated the diagnostic accuracy of these models. This analysis clearly illustrated that the advantage of the IOTA LR2 model and ultrasound-based SR compared with RMI-1 was most pronounced in premenopausal patients.
Unanswered questions and future research
Almost all diagnostic tests considered in this review, including the IOTA LR2 model and Simple rules, are based on women scheduled for surgery and use final histology as their reference standard. No information is available as to what percentages of women with masses were triaged for expectant management and if managed conservatively what the longterm outcome was for this group of women with respect to malignant transformation and possible complications such as torsion, rupture and haemorrhage which might also jeopardize ovarian function (Alcazar et al., 2005) . Accordingly there is a need for studies that examine the long-term outcome for masses classified as benign and treated expectantly without surgical intervention. In addition, more research is needed to develop risk prediction tools for multiple outcomes such as BOTs, early versus advanced stage invasive ovarian cancer and non-ovarian cancer metastasized to the ovary. Most prediction models used in clinical practice use a dichotomous outcome (i.e. benign or malignant). However, various subtypes of malignant disease are managed differently with implications for the type of surgery (i.e. fertility sparing Figure 4 Overview of summary point estimates for models considered in the quantitative data synthesis. All summary point estimates are displayed as sensitivity/specificity pairs with 95% CIs. For RMI-1, an additional HSROC curve was fitted.
Characterizing adnexal tumours before surgery Figure 5 Subgroup analysis of test performance of LR2, Simple Rules and RMI-1 in premenopausal (A, B and C, respectively) and post-menopausal women (D, E and F, respectively). LR2, logistic regression model 2; RMI-1, risk of malignancy index 1; SR, simple rules; Sens, sensitivity; LCL, lower confidence limit; UCL, upper confidence limit; Spec, specificity; GBE, Genk, Belgium; BCH, Beijing, China; PCR, Prague, Czech Republic; BIT, Bologna, Italy; CIT, Milano, Italy; VIT, Milano, Italy; GIT, Napoli, Italy; SIT, Sardinia, Italy; UDI, Udinese, Italy; LPO, Lublin, Poland; LSW, Lund, Sweden; QCCH, Queen Charlotte's and Chelsea Hospital, London, UK; SHH, Princess Anne Hospital, Southampton, UK.
surgery for BOT and early stage invasive ovarian cancer versus radical surgery), length of hospitalization and financial cost .
Conclusion
This update of a previous systematic review and meta-analysis shows that both IOTA LR2 and Simple Rules are currently the best diagnostic tests available for differentiating between the benign or malignant nature of an adnexal mass in a preoperative setting. In women of reproductive age, such differentiation is pivotal for preservation of fertility. Accordingly, healthcare policy makers should review current triaging protocols.
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